WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2022> 28> 3

Volume: 28 Issue: 3

1. Microbiome and metabolomics in alcoholic liver disease Page:580—582
2. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Page:425—472
3. Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke? Page:473—477
4. A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease Page:478—480
5. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease Page:565—574
6. Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults Page:481—482
7. Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients Page:553—564
8. Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study Page:540—552
9. Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4 Page:522—539
10. Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial Page:497—509
11. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma Page:575—579
12. Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults Page:510—521
13. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals Page:483—496
14. RNA interference as a novel treatment strategy for chronic hepatitis B infection Page:408—424
15. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance Page:396—407
16. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further? Page:380—395
17. Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound Page:362—379
18. The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection Page:351—361
19. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma Page:333—350